阅读说明：本技术 一种抗敏组合物及其面霜与制备方法 (Anti-allergy composition, anti-allergy cream and preparation method of anti-allergy composition ) 是由 王之宁 朱洪 杨霞卿 唐芳勇 于 2019-09-28 设计创作，主要内容包括：本发明公开一种抗敏组合物及其面霜与制备方法,旨在提供一种既能抑制炎症反应,又可以修复角质屏障功能,逐步增强皮肤耐受性的面霜；其技术方法：包括扭刺仙人掌茎提取物0.5-2份,膜荚黄芪根提取物0.07-0.36份,合欢花提取物0.02-0.09份,天麻根提取物0.02-0.09份,神经酰胺3 0.1-2份,4-叔丁基环己醇0.03-0.6份,龙胆提取物0.05-0.5％,积雪草提取物0.05-0.5份；属于化妆品技术领域。(The invention discloses an anti-allergy composition, a face cream and a preparation method thereof, and aims to provide a face cream which can inhibit inflammatory reaction, repair cutin barrier function and gradually enhance skin tolerance; the technical method comprises the following steps: comprises 0.5-2 parts of cactus stem extract, 0.07-0.36 part of astragalus membranaceus root extract, 0.02-0.09 part of albizia flower extract, 0.02-0.09 part of gastrodia elata root extract, 30.1-2 parts of ceramide, 0.03-0.6 part of 4-tert-butylcyclohexanol, 0.05-0.5 part of gentian extract and 0.05-0.5 part of centella asiatica extract; belongs to the technical field of cosmetics.)

1. An anti-allergy composition, comprising the following components: 0.5-2 parts of cactus stem extract, 0.07-0.36 part of astragalus membranaceus root extract, 0.02-0.09 part of albizia flower extract, 0.02-0.09 part of gastrodia elata root extract, 30.1-2 parts of ceramide, 0.03-0.6 part of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol, 0.05-0.5 part of gentian extract and 0.05-0.5 part of centella asiatica extract.

2. The anti-allergy composition according to claim 1, further comprising 0.05 to 0.27 parts of ledebouriella root extract and 0.04 to 0.18 parts of calendula extract.

3. The anti-allergy face cream is characterized by comprising the following components in percentage by mass based on 100% of the total mass:

phase A: the balance of water, 15-25% of humectant, 0.1-0.5% of p-hydroxyacetophenone and 0.1-1% of magnesium sulfate;

phase B: 4-20% of an emollient, 1.2-4% of a skin feel regulator, 1-2% of an oil phase thickening suspending agent, 2.1-5% of a W/O emulsifier, 0.1-2% of PEG-10 polydimethylsiloxane, 0.01-0.05% of jojoba oil and 0.1-0.5% of tocopherol acetate;

and C phase: 0.5-2% of cholla stem extract, 0.07-0.36% of astragalus membranaceus root extract, 0.02-0.09% of albizia flower extract, 0.02-0.09% of gastrodia elata root extract, 0.05-0.27% of saposhnikovia divaricata root extract, 0.04-0.18% of calendula officinalis extract, 30.1-2% of ceramide, 0.3-0.8% of 1, 3-propylene glycol (and) caprylyl hydroximic acid, 0.05-0.5% of gentian extract and 0.05-0.5% of centella asiatica extract;

phase D: 0.03-0.6% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

4. The anti-allergy cream according to claim 3, wherein the humectant is prepared from glycerol, propylene glycol and glyceryl polyether-26 in a mass ratio of 8-12: 6-10: 1-3, and mixing.

5. The anti-allergy cream according to claim 3, wherein the emollient is prepared from cyclopentadimethylsiloxane (and) cyclohexasiloxane, polydimethylsiloxane and isooctyl palmitate according to a mass ratio of 5-10: 2-5: 2-5 by mixing.

6. The anti-sensitivity cream according to claim 3, wherein the skin-feel modifier is prepared from polymethylsilsesquioxane, zinc oxide (and) triethoxyoctylsilane, polydimethylsiloxane (and) polydimethylsiloxane/vinyl polydimethylsiloxane crosspolymer in a mass ratio of 0.1-2: 0.1-2: 1-4 by mixing.

7. The anti-sensitivity cream according to claim 3, characterized in that the oil phase thickening suspending agent is cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate.

8. The anti-allergy cream according to claim 3, wherein the W/O emulsifier is cetyl PEG/PPG-10/1 polydimethylsiloxane and PEG-10 polydimethylsiloxane in a mass ratio of 2-4: 0.1-2 by weight.

9. A process for preparing an anti-sensitivity cream according to claim 3, comprising the following steps in sequence:

1) uniformly stirring phase B cyclopentadimethylsiloxane (and) cyclohexasiloxane, polydimethylsiloxane (and) polydimethylsiloxane/vinyl polydimethylsiloxane cross-linked polymer in the same container, and recording as a prefabricated product 1 for later use;

stirring B-phase polydimethylsiloxane, polymethylsilsesquioxane and zinc oxide, and then putting the mixture into a grinder to grind the mixture uniformly for later use to be recorded as a prefabricated product 2);

2) sequentially adding the phase A water, the glycerol, the propylene glycol, the glyceryl polyether-26, the p-hydroxyacetophenone and the magnesium sulfate into a water phase pot, stirring for 30-35 r/min, heating to 80-85 ℃, keeping the temperature for 10-20 min until the water phase material is uniformly dissolved and transparent, cooling to 40-50 ℃, adding the phase C material, keeping the temperature and stirring until the phase C material is uniformly and transparent for later use;

3) adding phase B materials, namely cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene glycol carbonate, cetyl PEG/PPG-10/1 polydimethylsiloxane, PEG-10 polydimethylsiloxane, the prefabricated product 1), the prefabricated product 2), isooctyl palmitate, jojoba oil and tocopheryl acetate into an oil phase pot in sequence, starting rapid stirring, uniformly and uniformly stirring the materials, heating to 80-85 ℃, and keeping the temperature and stirring for 8-12 min;

4) vacuumizing an emulsifying pot, filtering the material body in the oil phase pot by 200 meshes, pumping into the emulsifying pot, starting stirring for 30-35 r/min, homogenizing at high speed for 1-3 min, and cooling to 40-50 ℃; maintaining vacuum, adjusting the stirring speed to 35-40 r/min, slowly filtering the water phase material with 200 meshes, pumping into an emulsifying pot, controlling the time to be 35-40 min, pumping out the water phase material, and maintaining stirring for 5-8 min;

5) filtering by 200 meshes, adding the D phase material, stirring for 3-5 min until the material body is uniformly mixed, vacuumizing, starting stirring for 40-45 r/min, starting high-speed homogenization for 5-8 min, observing the consistency of the material body, stopping homogenization after the consistency is proper, stirring for 30-35 r/min, stirring for 8-10 min, cooling to 35-45 ℃, sampling, detecting, and discharging after the material is qualified.

Technical Field

The invention discloses an anti-allergy composition, in particular to an anti-allergy cream, and also discloses a preparation method of the cream, belonging to the technical field of cosmetics.

Background

Sensitive Skin (SS) refers to a high-response state of skin under physiological or pathological conditions, mainly occurs on face, and clinically shows subjective symptoms such as burning, stabbing pain, itching and tightness of skin when being stimulated by physical, chemical and mental factors, with or without objective signs such as erythema, scaling and telangiectasia.

The formation of sensitive skin is caused by the interaction of skin intrinsic factors and external factors, which causes the skin barrier function to be damaged, and when the skin is stimulated, the skin is inflamed, the sensory nerve signal input is increased, the immune response is enhanced, and the sensitive skin and the sensitive symptoms are generated. The intrinsic causes of skin sensitization are: genetics, race, sex, age, skin disease, and the like; the external factors are: exogenous irritants, sunlight, food, weather, air pollution and, external stress. In terms of mechanism, the sensitive muscles are mostly caused by the fact that the skin barrier function is damaged and external stimulation is applied, so that cells in the stratum corneum generate inflammatory reaction, and further symptoms such as skin redness, swelling, pain, pruritus and the like are caused. When the formula of the cosmetic is designed, active ingredients for inhibiting inflammatory reaction, relieving nerves and repairing stratum corneum barrier function can be added, so that the inflammatory reaction of skin is effectively relieved, the skin tolerance is enhanced, and the symptoms of sensitive muscles can be relieved.

With the increase of consumption level, people pay more and more attention to the health problem of skin, and the attention on sensitive skin is also increased year by year. Climate change, air pollution, and cosmetic types and component complexity increase the probability of sensitive skin and the possibility of skin irritation. Sensitive skin has a high incidence in all countries of the world, and the incidence reported in different regions has a large difference due to different investigation methods, namely 25.4% -89.9% in europe and about 50% in australia. The incidence rate of women is generally higher than that of men, the American women accounts for 22.3-50.9%, and the Asian women accounts for 40-55.98%.

At present, the brands aiming at sensitive muscles in the market include foreign brands such as mascot, Weizi and skin-care spring, and domestic brands such as Weinuona and Yuze. Foreign brands mostly take the extremely simple and mild formula as a selling point, and are more prone to preventing people with allergy or extremely light and sensitive skin. Domestic products mostly solve the problem of skin sensitivity of consumers by means of the effect of repairing skin barriers, and have slow effect or even no effect. For consumers who already have sensitive muscle symptoms such as redness, swelling, stabbing, pain, itching and the like, the products on the market at present are far from meeting the requirements of the consumers. The market therefore needs such products that can effectively alleviate the symptoms of sensitivity, even perfectly solve the sensitive afflictions.

At present, a plurality of raw materials with anti-allergy effects are declared on the market, and basically, the raw materials are divided into two categories, one category is directed at inflammatory reaction, and can inhibit various inflammatory factors, so that the inflammatory reaction is inhibited; another category is nerve soothing, which reduces discomfort due to inflammation by soothing nerves. However, the immune response in humans is systemic, and once inflammation is induced, it is amplified step by step, and the body feels immune response through the nervous system, which becomes the signal for turning on stronger immune response. Therefore, the effective anti-allergy raw material can comprehensively inhibit inflammatory factors as far as possible, and starts from a nerve channel, relieves nerves and cuts off inflammatory signal transmission. The traditional anti-allergy product idea is that the formula is generally simple and mild as much as possible, or an anti-allergy active ingredient is added in the concept, or an active ingredient for recovering the function of a cutin barrier is added, the formula is mild, the invasion of skin external irritant substances can be only reduced, and the anti-allergy product has no effective relieving effect on sensitive skin with inflammation reaction; the concept of adding anti-allergic active ingredients can not effectively inhibit inflammatory reaction; the addition of the active ingredient for restoring the barrier function of the cutin alone cannot inhibit inflammatory reaction, and the inflammatory reaction cannot control the barrier function of the skin and cannot be effectively repaired.

Disclosure of Invention

In view of the above problems, the first object of the present invention is a rehabilitation composition that proceeds simultaneously from the inhibition of inflammatory factors, nerve soothing, and restoration of the keratinous barrier function according to an anti-allergic mechanism.

The second purpose is to provide a cream which can inhibit inflammatory reaction, repair the function of horny barrier and gradually enhance the skin tolerance.

The third purpose of the invention is to provide a preparation method of the face cream, which adopts the face cream prepared by a water-in-oil system and quickly permeates active ingredients into the horny layer to exert the effect.

Therefore, the first technical scheme provided by the invention is as follows:

the first technical scheme provided by the invention is as follows:

an anti-allergy composition comprising the following components: 0.5-2 parts of cactus stem extract, 0.07-0.36 part of astragalus membranaceus root extract, 0.02-0.09 part of albizia flower extract, 0.02-0.09 part of gastrodia elata root extract, 0.1-2 parts of ceramide, 0.03-0.6 part of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol, 0.05-0.5 part of gentian extract and 0.05-0.5 part of centella asiatica extract.

Furthermore, the anti-allergy composition also comprises 0.05 to 0.27 part of radix sileris extract and 0.04 to 0.18 part of calendula extract.

The second technical scheme provided by the invention is as follows:

an anti-allergy cream comprises the following components in percentage by mass based on 100% of the total mass:

phase A: the balance of water, 15-25% of humectant, 0.1-0.5% of p-hydroxyacetophenone and 0.1-1% of magnesium sulfate;

phase B: 4-20% of an emollient, 1.2-8% of a skin feel regulator, 1-2% of an oil phase thickening suspending agent, 2.1-7% of a W/O emulsifier, 0.1-2% of PEG-10 polydimethylsiloxane, 0.01-0.05% of jojoba oil and 0.1-0.5% of tocopherol acetate;

and C phase: 0.5-2% of cholla stem extract, 0.07-0.36% of astragalus membranaceus root extract, 0.02-0.09% of albizia flower extract, 0.02-0.09% of gastrodia elata root extract, 0.05-0.27% of saposhnikovia divaricata root extract, 0.04-0.18% of calendula officinalis extract, 30.1-2% of ceramide, 0.3-0.8% of 1, 3-propylene glycol (and) caprylyl hydroximic acid, 0.05-0.5% of gentian extract and 0.05-0.5% of centella asiatica extract;

phase D: 0.03-0.6% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

Further, the anti-allergy cream comprises the humectant which is prepared from glycerol, propylene glycol and glyceryl polyether-26 in a mass ratio of 8-12: 6-10: 1-3, and mixing.

Further, the emollient is prepared from cyclopentadimethylsiloxane (and) cyclohexasiloxane, polydimethylsiloxane and isooctyl palmitate according to a mass ratio of 1-10: 1-5: 2-5 by mixing.

Further, the anti-allergy cream comprises a skin feel regulator which is prepared from polymethylsilsesquioxane, zinc oxide (and) triethoxyoctylsilane, polydimethylsiloxane (and) polydimethylsiloxane/vinyl polydimethylsiloxane cross-linked polymer according to a mass ratio of 0.1-2: 0.1-2: 1-4 by mixing.

Further, in the anti-allergy cream, the oil phase thickening suspending agent is cyclo-penta-dimethyl siloxane (and) distearyl dimethyl ammonium hectorite (and) propylene carbonate.

Further, in the anti-allergy cream, the W/O emulsifier is cetyl PEG/PPG-10/1 polydimethylsiloxane and PEG-10 polydimethylsiloxane according to the mass ratio of 2-5: 0.1-2 by weight.

The third technical scheme provided by the invention is as follows:

the preparation method of the anti-allergy cream sequentially comprises the following steps:

1) uniformly stirring phase B cyclopentadimethylsiloxane (and) cyclohexasiloxane, polydimethylsiloxane (and) polydimethylsiloxane/vinyl polydimethylsiloxane cross-linked polymer in the same easy-to-stir manner, and recording the mixture as a prefabricated product 1 for later use;

stirring B-phase polydimethylsiloxane, polymethylsilsesquioxane and zinc oxide, and then putting the mixture into a grinder to grind the mixture uniformly for later use to be recorded as a prefabricated product 2);

2) sequentially adding the phase A water, the glycerol, the propylene glycol, the glyceryl polyether-26, the p-hydroxyacetophenone and the magnesium sulfate into a water phase pot, stirring for 30-35 r/min, heating to 80-85 ℃, keeping the temperature for 10-20 min until the water phase material is uniformly dissolved and transparent, cooling to 40-50 ℃, adding the phase C material, keeping the temperature and stirring until the phase C material is uniformly and transparent for later use;

3) adding phase B materials, namely cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene glycol carbonate, cetyl PEG/PPG-10/1 polydimethylsiloxane, PEG-10 polydimethylsiloxane, the prefabricated product 1), the prefabricated product 2), isooctyl palmitate, jojoba oil and tocopheryl acetate into an oil phase pot in sequence, starting rapid stirring, uniformly and uniformly stirring the materials, heating to 80-85 ℃, and keeping the temperature and stirring for 8-12 min;

4) vacuumizing an emulsifying pot, filtering the material body in the oil phase pot by 200 meshes, pumping into the emulsifying pot, starting stirring for 30-35 r/min, homogenizing at high speed for 1-3 min, and cooling to 40-50 ℃; maintaining vacuum, adjusting the stirring speed to 35-40 r/min, slowly filtering the water phase material with 200 meshes, pumping into an emulsifying pot, controlling the time to be 35-40 min, pumping out the water phase material, and maintaining stirring for 5-8 min;

5) filtering by 200 meshes, adding the D phase material, stirring for 3-5 min until the material body is uniformly mixed, vacuumizing, starting stirring for 40-45 r/min, starting high-speed homogenization for 5-8 min, observing the consistency of the material body, stopping homogenization after the consistency is proper, stirring for 30-35 r/min, stirring for 8-10 min, cooling to 35-45 ℃, sampling, detecting, and discharging after the material is qualified. Compared with the prior art, the technical scheme provided by the invention has the following technical advantages:

the combination provided by the invention adopts the astragalus membranaceus root extract, the gentiana scabra bunge extract, the albizia julibrissin flower extract and the gastrodia elata root extract as main anti-allergic active substances, and adopts the calendula flower extract as the saposhnikovia divaricata root extract in an auxiliary manner, and the stimulation of inflammatory factors/media (IL-alpha, IL-6, TNF alpha and PGE2) to organisms is reduced by inhibiting the release of the inflammatory factors/media according to the monarch, minister, assistant and guide concept formula of the traditional Chinese medicine; the compound 4-tert-butylcyclohexanol acts on intercellular communication level-directly contacts with a specific nerve receptor, TRPV1 thermoreceptor, intercepts information to prevent contact with the nerve receptor, and enhances tolerance threshold of skin. As a sensitivity regulator, the cactus stem extract can reduce the flow of calcium ions in cell membranes, restore the sensitivity of skin to a normal level, purposefully relieve the prickling feeling and burning sensation of skin, increase the prickling cactus stem extract, effectively inhibit inflammatory factors, reduce the irritation of other components in the formula, and maintain and repair the cutin barrier structure by assisting with ceramide 3.

2, according to the anti-allergy mechanism, the technical scheme provided by the invention scientifically and strictly selects active raw materials for inhibiting various inflammatory factors, selects active ingredients for relieving nerve pathways, prepares water-in-oil system face cream, quickly permeates the active ingredients into the horny layer to play a role, thereby achieving the effects of inhibiting the inflammatory factors, relieving nerves and repairing the horny barrier, inhibiting inflammatory reaction, repairing the horny barrier and gradually enhancing the skin tolerance. And the introduced CAMVA experiment is used for carrying out an in-vitro test method of the stimulation of the valuable chemicals, the test result is good in predictability, the test is matched with a 3T3 cell neutral red uptake toxicity test recorded in an OECD (organic electro luminescence) guide at present, and the stimulation and the safety of the anti-allergy formula are evaluated in an all-round way from a tissue level to a cell level, so that the effective control on the safety of the anti-allergy formula is really realized.

Detailed Description

The technical solutions in the embodiments of the present invention are described below clearly and completely, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. For process parameters or conditions not specifically mentioned, it can be carried out with reference to conventional techniques.

Example 1

The invention provides an anti-allergy composition which comprises the following components in parts by weight: 0.5g of cactus stem extract, 0.07g of astragalus membranaceus root extract, 0.05g of saposhnikovia divaricata root extract, 0.04g of calendula officinalis flower extract, 0.02g of albizia julibrissin flower extract, 0.02g of gastrodia elata root extract, 30.1 g of ceramide, 0.1g of gentian extract, 0.2g of centella asiatica extract and 0.15g of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

The cream containing the anti-allergy composition of example 1 comprises the following components:

phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.5 percent of p-hydroxyacetophenone and 0.5 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane 10%, polydimethylsiloxane 3%, isooctyl palmitate 3%, polymethylsilsesquioxane 0.5%, zinc oxide (and) triethoxyoctylsilane 0.1%, polydimethylsiloxane (and) dimethicone/vinyl dimethicone crosspolymer 1%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 2%, cetyl PEG/PPG-10/1 dimethicone 2%, PEG-10 dimethicone 1%, jojoba oil 0.02%, tocopheryl acetate 0.2%;

and C phase: 0.5 percent of cactus stem extract, 0.07 percent of astragalus membranaceus root extract, 0.05 percent of divaricate saposhnikovia root extract, 0.04 percent of calendula officinalis extract, 0.02 percent of albizia flower extract, 0.02 percent of gastrodia elata root extract, 30.1 percent of ceramide, 0.1 percent of gentian extract, 0.2 percent of centella asiatica extract and 0.5 percent of 1, 3-propylene glycol (and) caprylyl hydroximic acid;

phase D: 0.15% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

Example 2

The invention provides an anti-allergy composition which comprises the following components in parts by weight: 1.2g of cactus stem extract, 0.15g of astragalus membranaceus root extract, 0.04g of albizia flower extract, 0.03g of gastrodia elata root extract, 31 g of ceramide, 0.3g of gentian extract, 0.3g of centella asiatica extract and 0.1g of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

The cream containing the anti-allergy composition of example 2 had the following components:

phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.5 percent of p-hydroxyacetophenone and 0.5 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane 10%, polydimethylsiloxane 3%, isooctyl palmitate 3%, polymethylsilsesquioxane 0.5%, zinc oxide (and) triethoxyoctylsilane 0.1%, polydimethylsiloxane (and) dimethicone/vinyl dimethicone crosspolymer 1%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 2%, cetyl PEG/PPG-10/1 dimethicone 2%, PEG-10 dimethicone 1%, jojoba oil 0.02%, tocopheryl acetate 0.2%;

and C phase: 1.2 percent of the cactus stem extract, 0.15 percent of the astragalus membranaceus root extract, 0.04 percent of the albizia flower extract, 0.03 percent of the gastrodia elata root extract, 31 percent of ceramide, 0.3 percent of the gentian extract, 0.3 percent of the centella asiatica extract and 0.5 percent of 1, 3-propylene glycol (and) caprylyl hydroximic acid;

phase D: 0.1% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

Example 3

The invention provides an anti-allergy composition which comprises the following components in parts by weight: 0.8g of cactus stem extract, 0.1g of astragalus membranaceus root extract, 0.05g of albizia flower extract, 0.04g of gastrodia elata root extract, 30.4 g of ceramide, 0.2g of gentian extract, 0.3g of centella asiatica extract and 0.5g of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

The cream containing the anti-allergy composition of example 3 had the following composition:

phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.5 percent of p-hydroxyacetophenone and 0.5 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane 10%, polydimethylsiloxane 3%, isooctyl palmitate 3%, polymethylsilsesquioxane 0.5%, zinc oxide (and) triethoxyoctylsilane 0.1%, polydimethylsiloxane (and) dimethicone/vinyl dimethicone crosspolymer 1%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 2%, cetyl PEG/PPG-10/1 dimethicone 2%, PEG-10 dimethicone 1%, jojoba oil 0.02%, tocopheryl acetate 0.2%;

and C phase: 0.8% of cholla stem extract, 0.1% of astragalus membranaceus root extract, 0.05% of albizia flower extract, 0.04% of gastrodia elata root extract, 30.4% of ceramide, 0.2% of gentian extract, 0.3% of centella asiatica extract and 0.5% of 1, 3-propylene glycol (and) caprylyl hydroxamic acid;

phase D: 0.5% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

Example 4

The invention provides an anti-allergy composition which comprises the following components in parts by weight: 1g of cactus stem extract, 0.25g of astragalus membranaceus root extract, 0.1g of saposhnikovia divaricata root extract, 0.05g of calendula officinalis extract, 0.05g of albizia julibrissin flower extract, 0.05g of gastrodia elata root extract, 30.3 g of ceramide, 0.05g of gentian extract, 0.5g of centella asiatica extract and 0.3g of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

The cream containing the anti-allergy composition of example 4 comprises the following components:

phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.5 percent of p-hydroxyacetophenone and 0.5 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane 10%, polydimethylsiloxane 3%, isooctyl palmitate 3%, polymethylsilsesquioxane 0.5%, zinc oxide (and) triethoxyoctylsilane 0.1%, polydimethylsiloxane (and) dimethicone/vinyl dimethicone crosspolymer 1%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 2%, cetyl PEG/PPG-10/1 dimethicone 2%, PEG-10 dimethicone 1%, jojoba oil 0.02%, tocopheryl acetate 0.2%;

and C phase: 1% of cholla stem extract, 0.25% of astragalus membranaceus root extract, 0.1% of saposhnikovia divaricata root extract, 0.05% of calendula officinalis flower extract, 0.05% of albizia julibrissin flower extract, 0.05% of gastrodia elata root extract, 30.3% of ceramide, 0.05% of gentian extract, 0.5% of centella asiatica extract and 0.5% of 1, 3-propylene glycol (and) caprylyl hydroximic acid;

phase D: 0.3% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

Example 5

The invention provides an anti-allergy composition which comprises the following components in parts by weight: 2g of cactus stem extract, 0.36g of astragalus membranaceus root extract, 0.27g of saposhnikovia divaricata root extract, 0.18 part of calendula officinalis extract, 0.09g of albizia julibrissin flower extract, 0.09g of gastrodia elata root extract, 30.6 g of ceramide, 0.5g of gentian extract, 0.05g of centella asiatica extract and 0.6g of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

The cream containing the anti-allergy composition of example 5 had the following composition:

phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.5 percent of p-hydroxyacetophenone and 0.5 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane 10%, polydimethylsiloxane 3%, isooctyl palmitate 3%, polymethylsilsesquioxane 0.5%, zinc oxide (and) triethoxyoctylsilane 0.1%, polydimethylsiloxane (and) dimethicone/vinyl dimethicone crosspolymer 1%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 2%, cetyl PEG/PPG-10/1 dimethicone 2%, PEG-10 dimethicone 1%, jojoba oil 0.02%, tocopheryl acetate 0.2%;

and C phase: 2% of cholla stem extract, 0.36% of astragalus membranaceus root extract, 0.27% of saposhnikovia divaricata root extract, 0.18% of calendula officinalis flower extract, 0.09% of albizia julibrissin flower extract, 0.09% of gastrodia elata root extract, 30.6% of ceramide, 0.5% of gentian extract, 0.05% of centella asiatica extract and 0.5% of 1, 3-propylene glycol (and) caprylyl hydroxamic acid;

phase D: 0.6% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

Example 6

The invention provides an anti-allergy composition which comprises the following components in parts by weight: 1g of cactus stem extract, 0.36g of astragalus membranaceus root extract, 0.27g of divaricate saposhnikovia root extract, 0.18 parts of calendula officinalis extract, 0.09g of albizia flower extract, 0.09g of gastrodia elata root extract, 30.1 g of ceramide, 0.5g of gentian extract, 0.05g of centella asiatica extract and 0.5g of 1, 3-propylene glycol (and) caprylyl hydroximic acid.

The cream containing the anti-allergy composition of example 6 comprises the following components: phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.3 percent of p-hydroxyacetophenone and 0.6 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane 8%, polydimethylsiloxane 4%, isooctyl palmitate 3.5%, polymethylsilsesquioxane 1%, zinc oxide (and) triethoxyoctylsilane 0.4%, polydimethylsiloxane (and) dimethicone/vinyl dimethicone crosspolymer 2%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 0.8%, cetyl PEG/PPG-10/1 dimethicone 2.5%, PEG-10 dimethicone 0.5%, jojoba oil 0.02%, tocopherol acetate 0.2%;

and C phase: 1% of cholla stem extract, 0.36% of astragalus membranaceus root extract, 0.27% of saposhnikovia divaricata root extract, 0.18% of calendula officinalis flower extract, 0.09% of albizia julibrissin flower extract, 0.09% of gastrodia elata root extract, 30.1% of ceramide, 0.5% of gentian extract, 0.05% of centella asiatica extract and 0.5% of 1, 3-propylene glycol (and) caprylyl hydroxamic acid;

phase D: 0.6% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

In order to better illustrate the anti-sensitivity advantages of the present application, comparative experimental examples of the technical solutions provided in the present application are given below.

Comparative example 1

The composition provided by the comparative example comprises the following components in parts by weight: 0.36g of astragalus membranaceus root extract, 0.27g of saposhnikovia divaricata root extract, 0.18 parts of calendula officinalis flower extract, 0.09g of albizia julibrissin flower extract, 0.09g of gastrodia elata root extract, 30.6 g of ceramide, 0.5g of gentian extract, 0.05g of centella asiatica extract and 0.6g of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

The cream containing the composition of comparative example 1 had the following composition:

phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.5 percent of p-hydroxyacetophenone and 0.5 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane 10%, polydimethylsiloxane 3%, isooctyl palmitate 3%, polymethylsilsesquioxane 0.5%, zinc oxide (and) triethoxyoctylsilane 0.1%, polydimethylsiloxane (and) dimethicone/vinyl dimethicone crosspolymer 1%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 2%, cetyl PEG/PPG-10/1 dimethicone 2%, PEG-10 dimethicone 1%, jojoba oil 0.02%, tocopheryl acetate 0.2%;

and C phase: 0.36% of astragalus membranaceus root extract, 0.27% of saposhnikovia divaricata root extract, 0.18% of calendula officinalis extract, 0.09% of albizia julibrissin flower extract, 0.09% of gastrodia elata root extract, 30.6% of ceramide, 0.5% of gentian extract, 0.05% of centella asiatica extract and 0.5% of 1, 3-propylene glycol (and) caprylyl hydroxamic acid;

phase D: 0.6% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

Comparative example 2

The invention provides an anti-allergy composition which comprises the following components in parts by weight: 2g of cactus stem extract, 0.6g of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol, 30.6 g of ceramide, 0.5g of gentian extract and 0.05g of centella asiatica extract.

The cream containing the composition of comparative example 2 had the following composition:

phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.5 percent of p-hydroxyacetophenone and 0.5 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane 10%, polydimethylsiloxane 3%, isooctyl palmitate 3%, polymethylsilsesquioxane 0.5%, zinc oxide (and) triethoxyoctylsilane 0.1%, polydimethylsiloxane (and) dimethicone/vinyl dimethicone crosspolymer 1%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 2%, cetyl PEG/PPG-10/1 dimethicone 2%, PEG-10 dimethicone 1%, jojoba oil 0.02%, tocopheryl acetate 0.2%;

and C phase: 2% of the cactus stem extract, 30.6% of ceramide, 0.5% of gentian extract, 0.05% of centella asiatica extract and 0.5% of 1, 3-propylene glycol (and) caprylyl hydroximic acid;

phase D: 0.6% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

Comparative example 3

The invention provides an anti-allergy composition which comprises the following components in parts by weight: 2g of cactus stem extract, 0.36g of astragalus membranaceus root extract, 0.27g of saposhnikovia divaricata root extract, 0.18 part of calendula officinalis extract, 0.09g of albizia julibrissin flower extract, 0.09g of gastrodia elata root extract and 0.6g of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

The cream containing the composition of comparative example 3 had the following composition:

phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.5 percent of p-hydroxyacetophenone and 0.5 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane 10%, polydimethylsiloxane 3%, isooctyl palmitate 3%, polymethylsilsesquioxane 0.5%, zinc oxide (and) triethoxyoctylsilane 0.1%, polydimethylsiloxane (and) dimethicone/vinyl dimethicone crosspolymer 1%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 2%, cetyl PEG/PPG-10/1 dimethicone 2%, PEG-10 dimethicone 1%, jojoba oil 0.02%, tocopheryl acetate 0.2%;

and C phase: 2% of the cactus stem extract, 0.36% of the astragalus membranaceus root extract, 0.27% of the saposhnikovia divaricata root extract, 0.18% of the calendula officinalis flower extract, 0.09% of the albizia julibrissin flower extract, 0.09% of the gastrodia elata root extract and 0.5% of 1, 3-propylene glycol (and) caprylyl hydroximic acid;

phase D: 0.6% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

Comparative example 4

An anti-allergy cream comprises the following components in percentage by mass based on 100% of the total mass:

phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.5 percent of p-hydroxyacetophenone and 0.5 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane 1%, polydimethylsiloxane 8%, isooctyl palmitate 4%, polymethylsilsesquioxane 0.5%, zinc oxide (and) triethoxyoctylsilane 0.5%, polydimethylsiloxane (and) dimethicone/vinyl dimethicone crosspolymer 2%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 1.5%, cetyl PEG/PPG-10/1 dimethicone 2%, PEG-10 dimethicone 2%, jojoba oil 0.05%, tocopheryl acetate 0.1%;

and C phase: 1% of cholla stem extract, 0.25% of astragalus membranaceus root extract, 0.1% of saposhnikovia divaricata root extract, 0.05% of calendula officinalis flower extract, 0.05% of albizia julibrissin flower extract, 0.05% of gastrodia elata root extract, 30.3% of ceramide, 0.05% of gentian extract, 0.5% of centella asiatica extract and 0.5% of 1, 3-propylene glycol (and) caprylyl hydroximic acid;

phase D: 0.3% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

Comparative example 5

An anti-allergy cream comprises the following components in percentage by mass based on 100% of the total mass:

phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.5 percent of p-hydroxyacetophenone and 0.5 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane ratio 6%, polydimethylsiloxane 3%, isooctyl palmitate 2%, polymethylsilsesquioxane 2%, zinc oxide (and) triethoxyoctylsilane 5%, polydimethylsiloxane (and) polydimethylsiloxane/vinyl polydimethylsiloxane crosspolymer 4%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 1%, cetyl PEG/PPG-10/1 polydimethylsiloxane 5%, PEG-10 polydimethylsiloxane 0.5%, jojoba oil 0.01%, tocopheryl acetate 0.5%;

and C phase: 2% of cholla stem extract, 0.36% of astragalus membranaceus root extract, 0.27% of saposhnikovia divaricata root extract, 0.18% of calendula officinalis flower extract, 0.09% of albizia julibrissin flower extract, 0.09% of gastrodia elata root extract, 30.6% of ceramide, 0.5% of gentian extract, 0.05% of centella asiatica extract and 0.5% of 1, 3-propylene glycol (and) caprylyl hydroxamic acid;

phase D: 0.6% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

Comparative example 6

An anti-allergy cream comprises the following components in percentage by mass based on 100% of the total mass:

phase A: the balance of water, 10 percent of glycerol, 8 percent of propylene glycol, 262 percent of glycerol polyether, 0.3 percent of p-hydroxyacetophenone and 0.6 percent of magnesium sulfate;

phase B: cyclopentadimethylsiloxane (and) cyclohexasiloxane 10%, polydimethylsiloxane 1%, isooctyl palmitate 1%, polymethylsilsesquioxane 3%, zinc oxide (and) triethoxyoctylsilane 0.1%, polydimethylsiloxane (and) dimethicone/vinyl dimethicone crosspolymer 1%, cyclopentadimethylsiloxane (and) disteardimonium hectorite (and) propylene carbonate 2%, cetyl PEG/PPG-10/1 dimethicone 0.1%, PEG-10 dimethicone 1%, jojoba oil 0.02%, tocopheryl acetate 0.2%;

and C phase: 1% of cholla stem extract, 0.36% of astragalus membranaceus root extract, 0.27% of saposhnikovia divaricata root extract, 0.18% of calendula officinalis flower extract, 0.09% of albizia julibrissin flower extract, 0.09% of gastrodia elata root extract, 30.1% of ceramide, 0.5% of gentian extract, 0.05% of centella asiatica extract and 0.5% of 1, 3-propylene glycol (and) caprylyl hydroxamic acid;

phase D: 0.6% of 1, 2-pentanediol (and) 4-tert-butylcyclohexanol.

1. The mildness of the chick embryo chorioallantoic membrane is verified by adopting a comparison test of a chick embryo chorioallantoic membrane blood vessel experiment.

In order to prove the advantages of the technical scheme provided by the application, a CAMVA experiment is adopted in the product detection of the embodiment of the application, the experiment is a world advanced in-vitro test method for evaluating the irritation of chemicals, the test result is good in predictability, the experiment is matched with a 3T3 cell neutral red uptake toxicity test which is recorded in OECD guidelines at present, the irritation and the safety of an anti-sensitive formula are evaluated in an all-around manner from a tissue level to a cell level, and the effective control on the safety of the anti-sensitive formula is really realized.

(1) The test method briefly describes:

chorioallantoic membrane vascular test (CAMVA) method the potential ocular irritancy is assessed by observing the effect of the test substance on the blood vessels, taking 14-day-old chick embryos, the test substance being in direct contact with a small area of the CAM, and observing CAM vascular changes such as bleeding or hyperemia (telangiectasia), vascular obliteration (ghost vessels) after 30 minutes of exposure, and the concentration of the test substance that causes 50% of the fertilized eggs to develop these lesions is considered the toxic endpoint. The CAMVA test requires the determination of the dose achieved by 50% positive reaction in 10 test chick embryos.

(2) And (4) result judgment standard:

TABLE 1-1 CAMVA test Scoring standards

Vascular effects	Scoring	Description of the Observation
			No reaction	0	No response was observed, CAM was normal
Ghost blood vessel	1	No bleeding in the blood vessel and clear blood vessel
			Capillary damage	2	Congestion, or increased CAM microvascular blood
Extreme slight hemorrhage	3	The coverage area of the fine bleeding point in the ring is less than 25 percent
			Mild hemorrhage	4	The coverage area of the intra-annular hemorrhage points is 25-50%
Moderate hemorrhage	5	The bleeding range of a large amount of bleeding points or small areas in the ring is 50 to 75 percent
			Severe hemorrhage	6	The intra-annular hemorrhage point area is more than 75 percent

TABLE 1-2 evaluation criteria for cosmetic irritation (CAMVA test) results

Tables 1-3 anti-allergic composition three-group combination irritation (CAMVA test) results

The experimental results show that the chick embryo test positive rate of the comparative examples 1 to 3 is high and is not qualified, the cream added with the anti-allergy composition of the examples 1 to 6 is qualified, which indicates that the extracts of the prickly pear and the astragalus membranaceus in the anti-allergy composition can obviously reduce the irritation of the whole formula, and the ceramide 3 can properly reduce the irritation but cannot obviously reduce the irritation of chemical components in the cream, and the chick embryo test shows that the anti-allergy composition can effectively reduce the irritation of products.

2. Volunteer pepper stimulation experiment (nerve relief) contrast test

The nerve soothing effect of the product is judged by performing clinical tests on the sensitive skin of 24 volunteers, observing and recording the pricking degree of the product of the embodiment, the product of the control example and the product of the blank group in the sensitive skin area of the volunteers.

Test area: both sides of the nasolabial sulcus

Test samples: face cream containing 31.6ppm capsaicin +/-face cream containing three groups of anti-allergy compositions and three control compositions

The test mode is as follows: applying for three minutes, and performing sensory evaluation

Evaluation criteria: 0 is not perceptible; 1 is barely perceptible; 2, slight feeling; 3-moderate sensation; 4 ═ has strong feeling

TABLE 2-1 volunteer test data

From the comparison experiment, the effect of the examples 3, 4 and 5 on relieving the tingling and burning sensation is obvious, compared with the blank group only added with the capsaicin, the number of people without the pain sensation (0) and with the slight pain sensation (1) is obviously increased, the irritation of the capsaicin to the skin is reduced in the trial process of the volunteers by the anti-allergy composition, and compared with the blank group only added with the capsaicin, the comparison examples 1, 2 and 3 are not improved, and the number of people with the tingling sensation is basically not different, which indicates that the sample of the comparison example cannot relieve the tingling sensation of the capsaicin. The same number of persons with no pain (0) and slight pain (1) was significantly increased in examples 3, 4 and 5 as compared with comparative examples 1, 2 and 3, indicating that the three groups of examples were effective in alleviating the burning sensation of stabbing pain.

3. Clinical efficacy-verified reduction of skin sensitivity

Sample: anti-allergy cream: cream of example 5 and cream of control 2 were added (one test was selected for each of the control and example because of the longer test period)

The application method comprises the following steps: subjects were instructed to cleanse their skin every morning, noon and evening and then apply the cream of example 5 and the cream of control 2 to their face (half-face test). The preparation is administered 1 times each day in the morning, at noon and at night. After two weeks of use, the facial symptoms of the subjects, such as skin sensitivity, itching, burning, stinging and tightness, and objective symptoms, such as erythema, edema, dryness and desquamation, were observed and statistically counted.

Reference standard

According to the Western medicine diagnosis and treatment standard of skin allergy and adverse reaction, and referring to the clinical research guiding principle of new traditional Chinese medicine as the curative effect judgment standard.

The subjects were from social recruiting volunteers, 30 in total, 24 women, 6 men. The age is 20-47 years. The clinical manifestations are patients with symptoms of easy skin allergy, poor tolerance, pruritus, red swelling, dry crack and the like.

TABLE 3-1 reduction of number of sensitive subjects in clinical trials of skin sensitivity

The specific proportions of the sensitive patients in different periods in the clinical verification of skin sensitivity reduction are shown in table 3-1, and the results show that after the cream containing the anti-sensitivity composition of example 5 is used, the evaluation of the overall improvement effect of the skin sensitivity of the subjects is 86.7% (26 persons) effective rate, wherein 66.7% (20 persons) results are 'significant', and 20% (6 persons) results are 'very significant'. Subjects 93.3% (28 people) considered the safety and tolerability of the triple anti-allergy cream containing composition to be "very good" or "good", with 53.3% (16 people) results being "very good" and 40% (12 people) rated as "good".

Data observation of cream in the control group 2 shows that after the astragalus membranaceus root extract, the saposhnikovia divaricata root extract, the calendula officinalis extract, the albizia julibrissin flower extract, the gastrodia elata root extract and the like of the anti-allergy composition are removed, the skin sensitivity of a subject is improved compared with that before the anti-allergy composition is used, but the improvement effect is not as obvious as that of the anti-allergy composition in example 5, and the anti-allergy composition is combined with the twisted cactus, the ceramide 3 and the like, so that the effect of reducing the skin sensitivity is better than that of cream lacking.

4. Performing sensory evaluation on the anti-allergy cream to evaluate the cream with optimal skin feeling

Sample: anti-allergy cream: the creams of examples 4-6 and the creams of controls 4-6 were added

The application method comprises the following steps: the subject takes a soybean grain size sample and applies the sample on the face by circling at constant speed.

Evaluation index: spreadability and skin-sticking property during use, and moisturizing degree, absorbability and greasy feeling after use, and evaluation of overall preference of the product 5 minutes after use

To demonstrate that the examples have a good skin feel experience, skin feel comparisons were made by examples 4-6 and comparative examples 4-6.

TABLE 4-1 skin feel test results for examples and comparative examples

From the above table, it can be seen that the emulsifier, cyclopentadimethylsiloxane (and) cyclohexasiloxane or dimethicone and polymethylsilsesquioxane and dimethicone (and) dimethicone/vinyl dimethicone crosspolymer are reasonably matched to obtain a product which spreads well, has fast moisture absorption and does not develop oily light. Too much emulsifier will affect the spreadability of the product, while too little will affect the product stability; more isooctyl palmitate is added, and the skin becomes oily after absorption; the polydimethylsiloxane (and) polydimethylsiloxane/vinyl polydimethylsiloxane cross-linked polymer is added in a proper amount, so that the powder smoothness of the product can be improved, and the better smearing experience is brought; the polymethylsilsesquioxane with a proper amount can absorb excessive oil to increase smooth feeling, and excessive polymethylsilsesquioxane can dry skin and increase mud rubbing feeling. Overall evaluation shows that the matching proportion of the emulsifier, the grease and the like in the examples 4-6 has better performance in sensory trial experience, the skin feel and the later greasy feel have comfortable use experience, and the overall skin feel experience is superior to that of the comparative examples 4-6, which indicates that the technical scheme provided by the application has reasonable components.

The above embodiments are preferred embodiments of the present invention, but the present invention is not limited to the above embodiments, and any other changes, modifications, substitutions, combinations, simplifications and equivalents which do not depart from the spirit and principle of the present invention are intended to be included within the scope of the present invention.